Therapeutic Use of Botulinum Toxin in Neurorehabilitation
The botulinum toxins (BTX), type A and type B by blocking vesicle acetylcholine release at neuro-muscular and neuro-secretory junctions can result efficacious therapeutic agents for the treatment of numerous di...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Toxicology |
| Online Access: | http://dx.doi.org/10.1155/2012/802893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The botulinum toxins (BTX), type A and type B by blocking vesicle
acetylcholine release at neuro-muscular and neuro-secretory junctions
can result efficacious therapeutic agents for the treatment of
numerous disorders in patients requiring neuro-rehabilitative
intervention. Its use for the reduction of focal spasticity following
stroke, brain injury, and cerebral palsy is provided. Although the
reduction of spasticity is widely demonstrated with BTX type A
injection, its impact on the improvement of dexterity and functional
outcome remains controversial. The use of BTX for the rehabilitation
of children with obstetrical brachial plexus palsy and in treating
sialorrhea which can complicate the course of some severe neurological
diseases such as amyotrophic lateral sclerosis and Parkinson's disease
is also addressed. Adverse events and neutralizing antibodies
formation after repeated BTX injections can occur. Since impaired
neurological persons can have complex disabling feature, BTX treatment
should be viewed as adjunct measure to other rehabilitative strategies
that are based on the individual's residual ability and competence and
targeted to achieve the best functional recovery. BTX therapy has high
cost and transient effect, but its benefits outweigh these
disadvantages. Future studies must clarify if this agent alone or
adjunctive to other rehabilitative procedures works best on functional
outcome. |
|---|---|
| ISSN: | 1687-8191 1687-8205 |